Tumor-targeted delivery of TAT-Apoptin fusion gene using Escherichia coli Nissle 1917 to colorectal cancer
Tumor-targeted delivery of TAT-Apoptin fusion gene using Escherichia coli Nissle 1917 to colorectal cancer
复制标题
使用大肠杆菌 Nissle 1917 将 TAT-Apoptin 融合基因肿瘤靶向递送至结直肠癌
DOI：
10.1016/j.mehy.2010.12.010
复制
发表时间：
2011-04-01
影响因子：
4.7
通讯作者：
Wang, Jiansheng
中科院分区：
文献类型：
--
作者：
Zhou, Suna;Zhang, Mingxin;Wang, Jiansheng
鉴于结直肠癌的高发病率和高死亡率，常规治疗的疗效有限且副作用严重，需要开发新的替代治疗。近年来的研究表明，靶向治疗作为一种替代治疗手段显示出良好的前景。我们假设构建一个重组非致病性大肠杆菌Nissle 1917（EcN），将TAT-凋亡素融合基因插入到该益生菌载体中，作为大肠癌患者的靶向治疗策略。与传统的肿瘤治疗方法相比，含有TAT-Apoptin融合基因的重组EcN具有肿瘤特异性定殖、分泌表达和高效细胞内递送的能力，因此能够降低副作用的发生率，提高治疗效率。(C)2010爱思唯尔有限公司保留所有权利。
In view of the high incidence and mortality of the colorectal cancer, the limited efficacy and serious adverse effect of the conventional treatment, a novel alternative treatment needs to be developed. Recent studies have demonstrated that the targeted therapy as an alternative treatment showed a promising prospect. We hypothesized that construct a recombination non-pathogenic Escherichia coli Nissle 1917 (EcN), inserting a fusion gene TAT-Apoptin into this probiotic vector, as a targeted therapy strategy for patients of colorectal cancer. Compared with conventional treatments for tumors, the recombination EcN containing TAT-Apoptin fusion gene is capable of tumor-specific colonization, secretary expression and efficient intracellular delivery and therefore able to reduce the incidence of side effect and promote the efficiency of treatment. (C) 2010 Elsevier Ltd. All rights reserved.